Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?

Diabetes and Metabolism

Volumn 41, Issue 6, 2015, Pages 6S21-6S27

  Darmon, P ^a,b   Raccah, D ^a,b  

^a HÔPITAL DE LA CONCEPTION   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Basal insulin; GLP 1 receptor agonists; Postprandial hyperglycaemia; Premeal insulin

Indexed keywords

ALBIGLUTIDE; BASAL INSULIN; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN GLULISINE; LIXISENATIDE; SHORT ACTING INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; PEPTIDE; VENOM;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; WEIGHT GAIN; AGONISTS; BLOOD; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MEALS; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOMS;

EID: 84953299332     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/S1262-3636(16)30005-2     Document Type: Article

References (48)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015, 38:140-149.
2. Riddle M, Umpierrez G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011, 34:2508-2514.
3. Holst JJ, Vilsbøll T Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab 2013, 15:3-14.
4. Balena R, Hensley IE, Miller S, Barnett AH Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2013, 15:485-502.
5. Vora J Combining incretin-based therapies with insulin. Realizing the potential in type 2 diabetes. Diabetes Care 2013, 36(Suppl2):S226-S232.
6. Vora J, Bain SC, Damci T, et al. Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes. Diabetes Metab 2013, 39:6-15.
7. Carris NW, Taylor JR, Gums JG Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs 2014, 74:2141-2152.
8. Tibaldi J Achieving glycemic goals with addition of incretin-based therapies to insulin in patients with type 2 diabetes mellitus. Am J Med Sci 2014, 347:491-501.
9. Levin PA, Zhang Q, Mersey JH, et al. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design. Clin Ther 2011, 33:841-850.
10. Ligthelm RJ, Mouritzen U, Lynggaard H, et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006, 114:511-519.
11. Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract 2011, 17:727-736.
12. Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DHW Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): A randomised, treat-to-target clinical trial. The Lancet Diabetes and Endocrinology 2014, 2:30-37.
13. Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW, Fahrbach JL Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther 2010, 32:896-908.
14. Miao R, Wei W, Baser O, Xie L Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine. Patient Prefer Adherence 2013, 7:951-960.
15. Rayman G, Profozic V, Middle M Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes. Diabetes Res Clin Pract 2007, 76:304-312.
16. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009, 11:45-52.
17. Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med 2012, 29:e13-e20.
18. Dailey G, Rosenstock J, Moses RG, Ways K Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004, 27:2363-2368.
19. Edelman SV, Liu R, Johnson J, Glass LC AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes. Diabetes Care 2014, 37:2132-2140.
20. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008, 31:20-25.
21. Raccah D, Haak TJ, Huet D, et al. Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: results of the OSIRIS study. Diabetes Metab 2012, 38:507-514.
22. Dailey G, Lin J, Wang E Efficacy and safety of a basal-bolus regimen of basal insulin plus insulin glulisine in patients with type 2 diabetes: A pooled analysis of 5 clinical trials. Diabetes 2012, 61:A284.
23. Raccah D, Bretzel RG, Owens D, Riddle M When basal insulin therapy in type 2 diabetes mellitus is not enough: what next?. Diabetes Metab Res Rev 2007, 23:257-264.
24. Tinahones FJ, Gross JL, Onaca A, Cleall S, Rodriguez A Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial. Diabetes Obes Metab 2014, 16:963-970.
25. Del Prato S, Lankisch M, Lin J, Wang E, Owens DR Efficacy and safety of a basal-plus regimen of insulin glargine plus insulin glulisine in patients with type 2 diabetes: A pooled analysis of 4 clinical trials. Diabetes 2012, 61:A297.
26. Lankisch MR, Owens DR, Wang E, Lin J, Del Prato S Basal-plus regimen of insulins glargine and glulisine is weight neutral across BMI groups. Diabetes 2012, 61:A710-A711.
27. Owens DR, Luzio SD, Sert-Langeron C, Riddle MC Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month "proof-of-concept" study. Diabetes Obes Metab 2011, 13:1020-1027.
28. Owens DR, Del Prato S, Lin J, Wang E, Lankisch M Impact of diabetes duration on efficacy and safety of a basal-plus regimen of insulin glargine plus once daily insulin glulisine: A Pooled analysis from 4 clinical trials. Diabetes 2012, 61:A599.
29. Riddle MC, Rosenstock J, Vlajnic A, Gao L Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab 2014, 16:396-402.
30. Raccah D, Lin J, Bahloul A, Wang E, Penfornis A Meta-analysis of efficacy and safety outcomes associated with the basal-plus regimen of insulin glargine and insulin glulisine among type 2 diabetes patients with HbA1c >8%. Diabetes 2012, 61:A620.
31. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008, 10:1178-1185.
32. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab 2012, 14:1081-1087.
33. Ceriello A, Novials A, Canivell S, et al. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes Care 2014, 37:1938-1943.
34. Eng C, Kramer CK, Zinman B, Retnakaran R Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014, 384:2228-2234.
35. Meier JJ, Rosenstock J, Hincelin-Méry A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 2015, 38:1263-1273.
36. Shao N, Kuang HY, Hao M, Gao XY, Lin WJ, Zou W Effects of exenatide on obesity and NAFLD with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev 2014, 30:521-529.
37. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2011, 154:103-112.
38. Rosenstock J, Shenouda SK, Bergenstal RM, et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 2012, 35:955-958.
39. Buse JB, Han J, Miller S, et al. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. Curr Med Res Opin 2014, 30:1209-1218.
40. Diamant M, Nauck MA, Shaginian R, 4B Study Group, et al. Glucagonlike peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 2014, 37:2763-2773.
41. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013, 36:2489-2496.
42. Seino Y, Min KW, Niemoeller E, Takami A Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012, 14:910-917.
43. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013, 36:2497-2503.
44. Rosenstock J, Hanefeld M, Gentile S, on behalf of the GetGoal-Duo2 Study investigators, et al. Advancing basal insulin glargine with prandial lixisenatide QD vs insulin glulisine QD or TID in T2DM: the GetGoal-Duo2 evidence-based trial (NCT01768559). Diabetes 2015, 64(Suppl1A):LB27-LB28.
45. Raccah D, Lin J, Wang E, et al. Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. J Diabetes Complications 2014, 28:40-44.
46. Davies M, Pratley R, Hammer M, et al. Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med 2011, 28:333-337.
47. Rosenstock JDM, Silvestre L, Souhami E, et al. Benefits of a fixed-ratio formulation of once-daily insulin glargine/lixenatide (LixiLan) vs glargine in type 2 diabetes (T2DM) inadequately controlled on metformin. Diabetes 2014, 63(Suppl 1):A87-A88.
48. Rosenstock J, Fonseca VA, Gross JL, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 2014, 37:2317-2325.